DE60330542D1 - Pharmazeutische Zubereitung enthaltend einen NMDA Rezeptor Agonisten für die Behandlung von Bewegungsstörungen - Google Patents

Pharmazeutische Zubereitung enthaltend einen NMDA Rezeptor Agonisten für die Behandlung von Bewegungsstörungen

Info

Publication number
DE60330542D1
DE60330542D1 DE60330542T DE60330542T DE60330542D1 DE 60330542 D1 DE60330542 D1 DE 60330542D1 DE 60330542 T DE60330542 T DE 60330542T DE 60330542 T DE60330542 T DE 60330542T DE 60330542 D1 DE60330542 D1 DE 60330542D1
Authority
DE
Germany
Prior art keywords
treatment
pharmaceutical preparation
receptor agonist
preparation containing
nmda receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60330542T
Other languages
English (en)
Inventor
Uriel Heresco-Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarah Herzog Memorial Hospital Ezrat Nashim Association
Original Assignee
Sarah Herzog Memorial Hospital Ezrat Nashim Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarah Herzog Memorial Hospital Ezrat Nashim Association filed Critical Sarah Herzog Memorial Hospital Ezrat Nashim Association
Application granted granted Critical
Publication of DE60330542D1 publication Critical patent/DE60330542D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60330542T 2003-02-06 2003-12-24 Pharmazeutische Zubereitung enthaltend einen NMDA Rezeptor Agonisten für die Behandlung von Bewegungsstörungen Expired - Lifetime DE60330542D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL154318A IL154318A (en) 2003-02-06 2003-02-06 Pharmaceutical compositions for the treatment of movement disorders

Publications (1)

Publication Number Publication Date
DE60330542D1 true DE60330542D1 (de) 2010-01-28

Family

ID=30011985

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60330542T Expired - Lifetime DE60330542D1 (de) 2003-02-06 2003-12-24 Pharmazeutische Zubereitung enthaltend einen NMDA Rezeptor Agonisten für die Behandlung von Bewegungsstörungen

Country Status (7)

Country Link
US (3) US8629105B2 (de)
EP (1) EP1444979B1 (de)
AT (1) ATE451917T1 (de)
CA (1) CA2454337C (de)
DE (1) DE60330542D1 (de)
ES (1) ES2336091T3 (de)
IL (1) IL154318A (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1383465B1 (de) 2001-03-29 2011-08-10 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
JP2006265177A (ja) * 2005-03-24 2006-10-05 Taiyo Kagaku Co Ltd チック障害改善用組成物
US20100048653A1 (en) * 2005-07-14 2010-02-25 The University Of British Columbia Neuroprotective modulation of nmda receptor subtype activities
US8604080B2 (en) * 2007-02-14 2013-12-10 W. Louis Cleveland High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
IL188681A0 (en) 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
WO2010053976A2 (en) * 2008-11-04 2010-05-14 Mclean Hospital Corporation Drug-enhanced neurofeedback
CN102575275A (zh) 2009-09-01 2012-07-11 Lz治疗公司 用于提取和纯化神经节苷脂的方法
WO2011028794A2 (en) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) * 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2013109929A1 (en) 2012-01-20 2013-07-25 Garnet Biotherapeutics, Inc. Methods of ganglioside production
US9040581B1 (en) 2013-02-21 2015-05-26 The Florida State University Research Foundation, Inc. Methods of treatment using D-serine
ES2763339T3 (es) 2013-05-28 2020-05-28 Sarah Herzog Memorial Hospital Ezrat Nashim Ass Uso de agonistas de NMDAR para el tratamiento de disfunción de receptores glutamatérgicos autoinmune
WO2015127558A1 (en) * 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
WO2016057454A1 (en) 2014-10-06 2016-04-14 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
US10639135B2 (en) 2017-11-07 2020-05-05 International Business Machines Corporation Temporal mandible data capture analysis and recommendation
JP7518765B2 (ja) * 2017-11-22 2024-07-18 コンサート ファーマシューティカルズ インコーポレイテッド Ｄ－セリンの重水素化類似体およびその使用
US11484519B2 (en) 2019-03-07 2022-11-01 Florida State University Research Foundation, Inc. D-serine inhibit neuroinflammation due to a brain injury
US20220313640A1 (en) * 2019-05-29 2022-10-06 Dario Doller Deuterated analogs of d-serine and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3795738A (en) * 1972-12-26 1974-03-05 Abbott Lab Use of l-propyl l-leucyl glycine amide to treat parkinson's disease
US3851055A (en) * 1973-03-01 1974-11-26 Abbott Lab Method of treating tardive dyskinesia using l-prolyl l-leucyl glycine amide
JPH02138A (ja) * 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
WO1997003677A1 (en) * 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
US6310085B1 (en) * 1997-10-03 2001-10-30 Clarencew Pty Ltd. Method for the treatment of neurological or neuropsychiatric disorders
IL139008A0 (en) * 1998-04-14 2001-11-25 Gen Hospital Corp Methods for treating neuropsychiatric disorders
ATE235244T1 (de) * 1998-10-30 2003-04-15 Merck Patent Gmbh Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
DOP2001000189A (es) * 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease

Also Published As

Publication number Publication date
US20040157926A1 (en) 2004-08-12
ES2336091T3 (es) 2010-04-08
IL154318A (en) 2010-05-31
US8629105B2 (en) 2014-01-14
US9029410B2 (en) 2015-05-12
US20140121254A1 (en) 2014-05-01
EP1444979A1 (de) 2004-08-11
US9271966B2 (en) 2016-03-01
US20140187597A1 (en) 2014-07-03
CA2454337C (en) 2013-02-05
ATE451917T1 (de) 2010-01-15
EP1444979B1 (de) 2009-12-16
CA2454337A1 (en) 2004-08-06
IL154318A0 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
DE60330542D1 (de) Pharmazeutische Zubereitung enthaltend einen NMDA Rezeptor Agonisten für die Behandlung von Bewegungsstörungen
EP2982696A3 (de) Behandlung von akuter lymphoblastenleukämie
PL1978912T3 (pl) Opakowanie dla produktów medycznych i podobnych
ATE488225T1 (de) Kaubare, lutschbare und verschluckbare tablette mit einer calciumhaltigen verbindung als wirkstoff
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
EP1637132A4 (de) Externes präparat zur behandlung von fussflechte
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
ES2195902T3 (es) Composicion que comprende esfingomielinasa alcalina para uso como preparacion dietetica, complemento alimenticio o producto farmaceutico.
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
WO2008128191A3 (en) Oral cephalotaxine dosage forms
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
MXPA02011465A (es) Sal de creatina que tiene eficacia terapeutica y nutricional mejorada y composiciones que contienen la misma.
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
ATE338567T1 (de) Pharmazeutische zubereitungen, wirkstoffe enthaltend, die sich für unerlaubte verabreichung anbieten
ITRM20030485A1 (it) Composizione a base di citicolina in associazione con vitamine per la prevenzione ed il trattamento di patolgie oculari.
WO2007046123A3 (en) Composition containing vitamins k and d as well as taurine for the preventio and treatment of osteoporosis
SE0203817D0 (sv) New composition
HK1079981A1 (en) A pharmaceutical preparation comprising a abacavirand alovudine and use thereof
NO20044519L (no) Hyperforinderivater, anvendelse derav samt formuleringer som inneholder dem
RU2003106768A (ru) Способ лечебного питания больных хроническим панкреатитом

Legal Events

Date Code Title Description
8364 No opposition during term of opposition